RxDoctor Payments DataLook up a doctor →

Brian Farah, MD

Psychiatry · Winston Salem, NCNPI 1174552079

Payments from drug & device makers

$605,063in general payments, 2019–2025

Across 821 payments — averaging $736.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$198K
  • Neurocrine Biosciences, Inc.$153K
  • E.r. Squibb & Sons, L.L.C.$118K
  • Alkermes, Inc.$82K
  • Teva Pharmaceuticals USA, Inc.$29K
  • Idorsia Pharmaceuticals US Inc$21K
  • plus $4K from 7 others

What the payments were for

  • Consulting fees$44,0677%
  • Speaking & faculty fees$508,94784%
  • Travel & lodging$36,9976%
  • Food & beverage$15,0532%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$605,063 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$25,472
Medicare patients
35
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate62$193,972
AristadaAripiprazole Lauroxil61$193,949
Abilify MaintenaAripiprazole53$142,960
Invega TrinzaPaliperidone Palmitate18$139,113
PerserisRisperidone11$29,977
Risperdal ConstaRisperidone Microspheres13$28,265
LybalviOlanzapine/Samidorphan Malate11$15,391
Clozapine120$7,277
Fluphenazine Hcl44$4,247
Paliperidone ErPaliperidone28$2,866
Chlorpromazine Hcl26$1,963
Benztropine Mesylate127$1,739
Aripiprazole51$1,452
Fluphenazine Decanoate13$1,307
Gabapentin74$1,107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta$433$361,34993 claims
Alkermes, Inc.Aristada, Lybalvi$81,912$209,34172 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$198,139$142,96053 claims
Indivior Inc.Perseris$13$29,97711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →